ALK and non-small cell lung carcinoma: In August 2011, crizotinib, a novel ALK tyrosine kinase inhibitor, was approved by the US FDA for the treatment of patients with locally advanced or metastatic non-small-cell lung carcinomas (NSCLCs) that are ALK-positive as detected by an FDA-approved test (i.e. Vysis ALK FISH Break-Apart Probe Kit) [1].